Title |
Rituximab for Children with Immune Thrombocytopenia: A Systematic Review
|
---|---|
Published in |
PLOS ONE, May 2012
|
DOI | 10.1371/journal.pone.0036698 |
Pubmed ID | |
Authors |
Yi Liang, Lingli Zhang, Ju Gao, Die Hu, Yuan Ai |
Abstract |
Rituximab has been widely used off-label as a second line treatment for children with immune thrombocytopenia (ITP). However, its role in the management of pediatric ITP requires clarification. To understand and interpret the available evidence, we conducted a systematic review to assess the efficacy and safety of rituximab for children with ITP. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | <1% |
India | 1 | <1% |
Germany | 1 | <1% |
Unknown | 119 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 20 | 16% |
Student > Master | 19 | 16% |
Researcher | 17 | 14% |
Other | 11 | 9% |
Student > Ph. D. Student | 11 | 9% |
Other | 27 | 22% |
Unknown | 17 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 71 | 58% |
Agricultural and Biological Sciences | 8 | 7% |
Biochemistry, Genetics and Molecular Biology | 5 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 4% |
Business, Management and Accounting | 2 | 2% |
Other | 10 | 8% |
Unknown | 21 | 17% |